research, research experience - pacific neuroscience, neurological patient care and research

research

introduction
areas of expertise
research experience
parametrics
subinvestigators
drug companies
CRO's
central laboratories
review boards
how to volunteer

research experience

When you volunteer for a clinical trial, you need to know that the center you are trusting with your health is staffed by experienced professionals. Dr. Sutton has participated as an investigator in over 42 FDA approved clinical trials, serving as a Principal Investigator in 28 of these studies. The following list testifies to the breadth and scope of his clinical research experience.

Studies with Dr. Sutton as Principal Investigator:

Years	Sponsor	Study No.	Research Protocol Title
2004-on	Ortho-Mcneil Pharmaceuticals	(CAPSS-237)	“A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Tramadol HCl/Acetaminophen for the Treatment of Painful Diabetic Neuropathy”.
2004 – on	Allergan	(191622-057)	“A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Safety Study of Pulmonary Function in Patients with Reduced Lung Function Treated with Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper Limb Poststroke Spasticity”.
2004 –on	Glaxo-Smith-Kline	(101468/228)	“Onset of Motor Complications”
2003 – on	Glaxo-Smith-Kline	(101468/249)	“A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)”
2003 – on	Glaxo-Smith-Kline	(LAM40124)	“An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy
2003 – on	Novartis Pharmaceutical	(CENA713BUS13)	“Multi-Center Study Evaluating the Efficacy and Safety of Exelon (rivastigmine tartrate) 3-12 Mg/Day in Patients with Mild to Moderate Alzheimer’s Disease Who Are Responding Poorly to Aricept (donezepil)Treatment”
2003 – on	Pharmacia & Upjohn	(M/2760/0011)	“Open-Label, Long Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson’s Disease”
2003 – on	Pharmacia	(DA2APD-0075-031)	“A Phase III, Double-Blind, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanirole vs. Placebo in Patients with Early Parkinson’s Disease”.
2003 – on	Ortho-Mcneil	(CAPSS-149)	“A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Essential Tremor”.
2003 – on	Skye Pharma, Inc.	(SKF 101468164)	“An Open-Label, Randomized, Two Part Study to Investigate the Relative Bioavailability of Ropinirole CR and IR Formulations and the Effect of Food on the Pharmacokinetics of Ropinirole CR Formulation in Early Stage Parkinson’s Disease Patients”.
2003 – on	Teva Neuroscience	(EP002)	“A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson’s Disease Patients”.
2002 - on	Cephalon, Inc	[PRECEPT]	“A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients with Early Parkinson’s Disease.”
2002 - on	Kyowa Pharmaceutical, Inc	[KYOWA 6002-US-006]	“A 12 Week, Double Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day KW –6002 As Treatment for Parkinson’s Disease in Patients with Motor Response Complications On Levodopa/Carbidopa Therapy.”
2002 - 2003	Fujisawa Research Institute of America, Inc.	[FA-960-005]	“A Well Controlled Safety and Efficacy Study of FK960 in Subjects with Mild to Moderate Alzheimer’s Disease.”
2002 – on	Parkinson’s Study Group/ NIH	[PROGENI ]	“Parkinson’s Disease Collaborative Study of Genetic Linkage.”
2001 – 02	Janssen Research Foundation	[GAL-INT-26]	“A Randomized , Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Galantamine in the Treatment of Vascular Dementia.”
2001 –02	Janssen Research Foundation	[GAL-INT-10]	“A Randomized , Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Galantamine in the Treatment of Dementia of the Alzheimer’s Type.”
2001 – 2003	Skyepharma	[SKYE – 2004C/101468/167]	“A Phase II, Randomized, Double-Blind, Active-Controlled Study to Determine the Optimal Initial Titration Regimen of Ropinirole CR Tablets in Parkinson’s Disease Patients Not Receiving Other Dopaminergic Therapies.”
2000 – 2003	R.W. Johnson Pharmaceutical Research Institute	[TOPMAT-MIGR-001]	“A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine.”
2000 – on	Teva Clinical Research, Inc.	[TVP-1012/133]	“A Mulitcenter, US and Canada, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson’s Disease Patients with Motor Fluctuations.”
2001 – 2001	Janssen Research Foundation	[GAL-INT-5]	“A Randomized , 24-Week, Double-Blind, Placebo-Controlled, Flexible Dose Trial to Compare the Efficacy and Safety of Galantamine Hydrobromide to Placebo in Patients with Dementia with Lewy Bodies
2000 – 2001	Kyowa Pharmaceuticals, Inc.	[6002-USA-001]	“ A 12 Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group, Multicenter, Exploratory Study of the Safety and Efficacy of KW-6002 As Adjunctive Therapy in Patients with Parkinson’s Disease Who Have Motor Response Complications On Levodopa/Carbidopa.”
2000 – 2001	Amgen Inc.	[ 20000105]	“Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Month Safety, Efficacy, and Neuroimaging Trial of AMG-474-00 in the Treatment of Patients with Parkinson’s Disease.”
1998 - 2000	Ipsen Ltd	[DYSP-045]	“A Phase III Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport for the Treatment of Cervical Dystonia.”
1997 - 2000	Somerset Pharmaceuticals, Inc.	[S9303-E109-97B]	“Placebo-Controlled, Double-Blind Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System (STS) in Parkinson's Disease Patients Experiencing Sub-Optimal Responses to Levodopa-Carbidopa.”
1997 - 1999	F. Hoffman-La Roche Ltd	[M35011]	“A Long-Term Double-Blind Comparison of Tolcapone Versus Placebo Given in Combination with Levodopa/AADC-1 in Delaying the Onset of Motor Fluctuations in PD Patients Naļve to Levodopa Therapy.”
1997-1998	Allergan	[191622-004]	“An Open-Label, Multicenter Clinical Evaluation of the Safety of Intramuscular Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex Manufactured From Neurotoxin Complex Batch BCB2024 in the Management of Cervical Dystonia.”
1997	Allergan	[BTOX-140-8051]	“A Randomized, Multicenter, Double Blind, Placebo-Controlled Study of Intramuscular Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Cervical Dystonia.”

Studies with Dr. Sutton as Investigator:

Years	Sponsor	Study No.	Research Protocol Title
1998 - 2000	Cyberonics, Inc.	[T-01]	“The Use of Vagus Nerve Stimulation As A Treatment in Tremor”
1997 - 1998	Eisai, Inc	[E2020-A001-307]	“A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease.”
1996 - 1997	Zeneca & Glaxo Wellcome		“Protocol For a Multicentre, Long Term Study to Maximize Migraine Relief with 311C90 (MAXIMM).”
1996 - 1997	Parke-Davis Pharmaceutical Research	[970-68]	“A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multicenter Study of Tacrine (Ci-970) Once-A-Day Formulation (Tacrine Gits) with A 16-Month Open-Label Extension in Patients with Dementia of the Alzheimer’s Type”
1996 – 1997	Eisai America, Inc.	[E2020-A001-313]	“An Open-Label, Multicenter Clinical Trial Evaluating the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients with Alzheimer’s Disease.”
1996 - 1997	Interneuron Pharmaceuticals	[IP302-007]	“A Placebo-Controlled Study to Determine the Effects of 500 Mg Citicoline in Ischemic Stroke Patients.“
1996 - 1998	Hoechst-Marion-Roussel Pharmaceuticals, Inc.		“A 48 Week Study to Compare the Efficacy and Safety of Propentofylline (HWA 285) with Placebo in Outpatients with Alzheimer’s Disease.”
1996 - 1998	Hoechst-Marion-Roussel Pharmaceuticals, Inc.		“A 24 Week Study to Compare the Efficacy and Safety of Propentofylline (HWA 285) with Placebo in Outpatients with Vascular Dementia.”
1995 - 1996	Janssen Pharmaceutica		“Lubelozole: Effects of Intravenous Therapy in Subjects with Acute Ischemic Stroke. A Placebo-Controlled, Double-Blind, Randomized, Multicenter Trial.”
1994 - 1995	Athena Neurosciences		“A Double-Blind, Placebo-Controlled, Single Dose, Dose-Finding Safety, Tolerability and Preliminary Efficacy Study of BOTB (Botulinum Toxin Type B) in Patients with Idiopathic Cervical Dystonia.”
1993	Boehringer-Ingelheim		“Double-Blind, Placebo Controlled, Parallel Group Comparison to Assess the Safety, Tolerance, and Efficacy of Pramiprexole in Advanced Parkinson’s Disease and to Assess the Long-Term Safety with Open-Label Pramiprexole.”
1992 - 1993	Adria Laboratories		“A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Cabergoline in Patients with Parkinson’s Disease.”
1992 - 1993	Smithkline Beecham		“A Multicentre Double-Blind, Placebo Controlled Study of Oral Doses of Ropinerole in Parkinsonian Patients Not Previously Treated with Anti-Parkinson Therapy.”
1992 - 1993	Smithkline Beecham		“A Double-Blind, Placebo Controlled, Parallel Group Study of Oral Doses of Ropinerole for Six Month’s Treatment as Adjunct Therapy in Parkinsonian Patients Not Optimally Controlled on L-Dopa (DCI).”

parametrics >>